Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Huashan Hospital: Clinical Trials & FDA Approval Profile

Huashan Hospital (Global / Institutional) sponsors 32 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 20 active protocols (13 recruiting now), 4 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)103 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Huashan Hospital
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)32
Active Pipeline (Recruiting Now)20 (13)
Completed vs Stopped Early4 / 0 (0.0%)
Median Closed Actual Enrollment103 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Huashan Hospital
Hospital Research SiteLocationShared Protocols
Huashan Hospital, Fudan UniversityShanghai, Shanghai Municipality10

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Huashan Hospital
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07185373Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSLPhase II/IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Huashan Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI